Heidi Rommelaere

USPTO Granted Patents = 9 (Patent Applications = 11)

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 1 (Patent Applications = 12)

Average Co-Inventor Count = 8.8

ph-index = 2

Forward Citations = 14(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12509522 - POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND OX40L (2025-12-30),

2. 12384840 - Nucleic acids encoding polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP (2025-08-12),

3. 11897951 - Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α (2024-02-13),

4. 11840566 - Methods of treating asthma with polypeptides targeting IL-13 and TSLP (2023-12-12),

5. 11773159 - Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same (2023-10-03),

6. 11332525 - Polypeptides comprising immunoglobulin single variable domains targeting TNFA and IL-23 (2022-05-17),

7. 11208476 - Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP (2021-12-28),

8. 10829552 - Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same (2020-11-10),

9. 10017568 - Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same (2018-07-10),

Title: The Innovative Journey of Heidi Rommelaere in Biopharmaceuticals

Introduction

Heidi Rommelaere, an accomplished inventor based in Ghent, Belgium, has made significant strides in the field of biopharmaceuticals with a portfolio of eight patents. Her contributions largely center on the development of innovative drugs aimed at treating inflammatory and autoimmune diseases, showcasing her dedication to advancing medical science.

Latest Patents

Among her latest patents, Heidi has developed nucleic acids encoding polypeptides comprising immunoglobulin single variable domains that target IL-13 and TSLP. This groundbreaking technology aims to provide a novel drug for treating subjects suffering from inflammatory diseases. The polypeptides in this invention are characterized by containing at least four immunoglobulin single variable domains (ISVDs), with at least two binding to IL-13 and at least two binding to TSLP. Additionally, Heidi's work includes polypeptides targeting IL-6 and TNF-α, which offers a new approach for treating autoimmune conditions such as rheumatoid arthritis. This disclosure outlines polypeptides with at least three ISVDs, where one binds to TNF-α and two bind to IL-6, along with associated nucleic acids, vectors, and compositions.

Career Highlights

Heidi has a noteworthy career with impactful roles in prominent biopharmaceutical companies. She has worked with Ablynx N.V. and Sanofi, where she contributed her expertise and innovative ideas to the development of cutting-edge therapies. Her work has been crucial in shaping the direction of therapeutic solutions in her field.

Collaborations

Throughout her career, Heidi has collaborated with talented professionals, including her coworkers Ann Brigé and Sigrid Cornelis. These collaborations have fostered a rich environment for innovation, allowing Heidi to enhance her research and development efforts.

Conclusion

Heidi Rommelaere stands out as a leading inventor in the biopharmaceutical sector, with a remarkable track record of patents and collaborations. Her ongoing work promises to further impact the treatment of inflammatory and autoimmune diseases, solidifying her reputation as a visionary in the realm of medical innovations.

This text is generated by artificial intelligence and may not be accurate.